Boost as $30m funding secured for medtech pioneer WhiteSwell

Awareness of heart failure is increasing, particularly locally with Galway native Michael Lyster living with the condition and sharing his experience.

Heart failure is a growing health problem and a leading cause of hospitalization worldwide. When the heart does not work as efficiently as it should, over time, this can progress to cause shortness of breath, congestion and fluid build-up.

This ultimately leads to a hospital admission, poor quality of life and short life expectancy. Medtech pioneer WhiteSwell, based in Galway, aims to do something about it.

Having developed an innovative therapy built on insights gained from deep research into the complex fluid dynamics of the heart, WhiteSwell recently announced a $30m funding, led by US healthcare investors RA Capital and InCube along with local investor WDC. “Heart failure is an enormous clinical problem affecting millions of families worldwide,” said CEO Eamon Brady, who previously founded and led Neuravi, the Galway medtech success story acquired by Johnson & Johnson in 2017.

“Our unique approach aims to get acute heart failure patients out of hospital quicker and healthier, and to slow the typical cycle of deterioration and rehospitalization,” he said.

WhiteSwell is currently recruiting a Vice President of Research and Development as well as hiring technical operations and quality engineers. To learn more about heart failure, check out the website or and


Page generated in 0.2418 seconds.